. Author manuscript; available in PMC: 2018 Jun 1.

Published in final edited form as: Pediatr Infect Dis J. 2017 Jun;36(6):539–544. doi: 10.1097/INF.0000000000001495

Table 2.

Primary clinical outcomes.

Outcome	RV-A vs non-RV	RV-C vs non-RV	RV-C vs RV-A

	HR (95% CI)	HR (95% CI)	HR (95% CI)
A new physician-confirmed wheezing episode within 12 months after discharge	3.9 (1.7, 9.0) p = 0.009	3.9 (1.9, 7.9) p = 0.001	0.99 (0.53, 1.9) p = 0.98
A new physician-confirmed RV induced wheezing episode within 12 months after discharge	4.5 (1.4, 14) p = 0.001	5.0 (1.9, 13) p < 0.001	1.1 (0.50, 2.5) p = 0.79
Initiation of controller medication for asthma symptoms within 12 months after discharge	4.7 (1.6, 14) p = 0.004	3.2 (1.2, 8.5) p = 0.017	0.69 (0.34, 1.4) p = 0.31

Univariable Cox regression analysis was used to analyze the risk for primary clinical outcomes. HR for the difference between RV-A vs non-RV, RV-C vs non-RV and RV-C vs RV-A. HR, hazard ratio; CI, confidence interval; RV, rhinovirus. Statistically significant results are marked with bold.